Novo Nordisk has partnered with three telehealth firms to expand access to its weight-loss drug, Wegovy. This move is part of the company’s effort to reach cash-paying customers. Previously, Wegovy was available through local pharmacies and Novo Nordisk’s direct-to-consumer pharmacy program, NovoCare.
Dave Moore, executive vice president of U.S. Operations and president of Novo Nordisk, explained, “We wanted to ensure that we could provide real Wegovy at the same place patients are receiving care.”
This announcement comes after a U.S. judge rejected a bid by compounding pharmacies to continue making copies of Novo Nordisk’s drugs, Ozempic and Wegovy.
In March, Novo Nordisk launched NovoCare, offering the drug at a reduced cost of $499 for self-paying patients. Customers can now access Wegovy through a bundled offering starting at $599 monthly, which includes membership and access to all Wegovy doses.
Hims & Hers’ shares increased by 29.9% in premarket trading following the announcement. The company will continue to offer personalized compounded versions of semaglutide on its platform.
Zach Reitano, CEO of Ro, stated, “Adding Novo Nordisk’s FDA-approved treatments at the best available cash price will help more patients nationwide get the obesity care they need.”
— new from Reuters